Novartis MS drug wins FDA's blessing amid scrutiny of $88,000 annual price

Novartis AG has won U.S. Food and Drug Administration approval for multiple sclerosis drug Mayzent as the Swiss company targets patients whose disease advances from intermittent attacks to a gradually worsening condition.

from Reuters: Health News https://ift.tt/2V3T3Q0